Pseudoxanthoma Elasticum Clinical Trial
Official title:
Characterization of Patients With Pseudoxanthoma Elasticum
Verified date | June 2018 |
Source | University Hospital, Bonn |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Pseudoxanthoma elasticum (PXE) is a rare multisystem disorder of autosomal recessive inheritance (OMIM# 264800) and an estimated prevalence between 1:25.000 and 1:100.000. PXE is characterized by calcification and fragmentation of connective tissue rich in elastic fibers. Due to its high content of elastic fibers, Bruch Membrane in eyes of patients affected by PXE becomes thickened and calcified. The ocular phenotype is characterized by angioid streaks and peau d'orange but also choroidal neovascularizations and chorioretinal atrophy thereby in part mimicking the phenotype of age-related macular degeneration. The disease is due to mutations of the ABCC6-gene coding for a transmembrane protein which is mainly expressed in the liver and kidney. It is hypothesized that ABCC6 is involved in the excretion of a yet unknown factor from the liver which inhibits systemic calcification. In animal models several candidates for this factor have been identified but direct evidence for such a factor in patients with PXE is still missing. The primary purpose of this study is to further investigate the ocular phenotype of patients with PXE using multimodal imaging and functional testing to delineate the impact of Bruch membrane pathology on the eye. Furthermore, possible systemic anti-calcification factors, as well as associations with the vascular alterations are investigated to gain more insights into the pathogenesis of PXE..
Status | Active, not recruiting |
Enrollment | 100 |
Est. completion date | December 2018 |
Est. primary completion date | December 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Diagnosis of Pseudoxanthoma elastcium based on histopathologic and/or genetic testing |
Country | Name | City | State |
---|---|---|---|
Germany | Department of Ophthalmology, University of Bonn | Bonn | NRW |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Bonn |
Germany,
Charbel Issa P, Finger RP, Götting C, Hendig D, Holz FG, Scholl HP. Centrifugal fundus abnormalities in pseudoxanthoma elasticum. Ophthalmology. 2010 Jul;117(7):1406-14. doi: 10.1016/j.ophtha.2009.11.008. Epub 2010 Mar 1. — View Citation
Charbel Issa P, Finger RP, Holz FG, Scholl HP. Multimodal imaging including spectral domain OCT and confocal near infrared reflectance for characterization of outer retinal pathology in pseudoxanthoma elasticum. Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5913-8. doi: 10.1167/iovs.09-3541. Epub 2009 Jun 24. — View Citation
Charbel Issa P, Gliem M, Holz FG, Knabbe C, Hendig D. [Pseudodominant inheritance of pseudoxanthoma elasticum]. Ophthalmologe. 2015 Aug;112(8):686-90. doi: 10.1007/s00347-014-3231-9. Review. German. — View Citation
Finger RP, Charbel Issa P, Ladewig M, Götting C, Holz FG, Scholl HP. Fundus autofluorescence in Pseudoxanthoma elasticum. Retina. 2009 Nov-Dec;29(10):1496-505. doi: 10.1097/IAE.0b013e3181aade47. — View Citation
Finger RP, Fenwick E, Marella M, Charbel Issa P, Scholl HP, Holz FG, Lamoureux EL. The relative impact of vision impairment and cardiovascular disease on quality of life: the example of pseudoxanthoma elasticum. Health Qual Life Outcomes. 2011 Dec 12;9:113. doi: 10.1186/1477-7525-9-113. — View Citation
Gliem M, Fimmers R, Müller PL, Brinkmann CK, Finger RP, Hendig D, Holz FG, Charbel Issa P. Choroidal changes associated with Bruch membrane pathology in pseudoxanthoma elasticum. Am J Ophthalmol. 2014 Jul;158(1):198-207.e3. doi: 10.1016/j.ajo.2014.04.005. Epub 2014 Apr 13. — View Citation
Gliem M, Finger RP, Fimmers R, Brinkmann CK, Holz FG, Charbel Issa P. Treatment of choroidal neovascularization due to angioid streaks: a comprehensive review. Retina. 2013 Jul-Aug;33(7):1300-14. doi: 10.1097/IAE.0b013e3182914d2b. Review. — View Citation
Gliem M, Hendig D, Finger RP, Holz FG, Charbel Issa P. Reticular pseudodrusen associated with a diseased bruch membrane in pseudoxanthoma elasticum. JAMA Ophthalmol. 2015 May;133(5):581-8. doi: 10.1001/jamaophthalmol.2015.117. Erratum in: JAMA Ophthalmol. 2015 May;133(5):621. — View Citation
Gliem M, Müller PL, Birtel J, Hendig D, Holz FG, Charbel Issa P. Frequency, Phenotypic Characteristics and Progression of Atrophy Associated With a Diseased Bruch's Membrane in Pseudoxanthoma Elasticum. Invest Ophthalmol Vis Sci. 2016 Jun 1;57(7):3323-30. doi: 10.1167/iovs.16-19388. — View Citation
Gliem M, Müller PL, Birtel J, McGuinness MB, Finger RP, Herrmann P, Hendig D, Holz FG, Charbel Issa P. Quantitative Fundus Autofluorescence in Pseudoxanthoma Elasticum. Invest Ophthalmol Vis Sci. 2017 Dec 1;58(14):6159-6165. doi: 10.1167/iovs.17-22007. — View Citation
Gliem M, Zaeytijd JD, Finger RP, Holz FG, Leroy BP, Charbel Issa P. An update on the ocular phenotype in patients with pseudoxanthoma elasticum. Front Genet. 2013 Apr 4;4:14. doi: 10.3389/fgene.2013.00014. eCollection 2013. — View Citation
* Note: There are 11 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Ocular phenotype | Patients are investigated using a multimodal imaging approach and visual function testing. | patients will be followed longitudinally with an expected 1-year average interval between visits | |
Secondary | Biomarkers in PXE | Potential systemic biomarkers are investigated by collecting blood samples of PXE patients | 1 day (first visit) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02537054 -
Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)
|
Phase 2 | |
Completed |
NCT05569252 -
A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
|
Phase 2 | |
Recruiting |
NCT05662085 -
Progression Rate of Pseudoxanthoma Elasticum-associated Choroidal and Retinal Degeneration
|
||
Completed |
NCT03070860 -
What's Happen Under the Calcification Process in Pseudoxanthoma Elasticum
|
N/A | |
Completed |
NCT01446393 -
Functional and Structural Characterization of Arteriopathy in Pseudoxanthoma Elasticum (PXE)
|
N/A | |
Completed |
NCT00470977 -
Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT03758534 -
Natural History of GACI With or Without ARHR2 or PXE
|
||
Recruiting |
NCT05734196 -
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
|
Phase 1 | |
Not yet recruiting |
NCT06462547 -
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
|
Phase 2 | |
Recruiting |
NCT01446380 -
Phenotypic Expressions in a French Pseudoxanthoma-Elasticum Cohort
|
N/A | |
Recruiting |
NCT03813550 -
Intestinal Microbiota and Vitamin K Levels in PXE Patients (IMPROVE Study)
|
N/A | |
Not yet recruiting |
NCT03364504 -
Biological Collection of Kidney Cells
|
N/A | |
Recruiting |
NCT01731080 -
Arterial Wall Calcium Load in Pseudoxanthoma Elasticum
|
N/A | |
Completed |
NCT00555113 -
Evolution of Visual Impairment During Pseudoxanthoma Elasticum
|
N/A | |
Completed |
NCT00341419 -
Genetic Analysis of Patients With Pseudoxanthoma Elasticum
|
||
Withdrawn |
NCT04441671 -
Oral Pyrophosphate Absorption in PXE Disease
|
Phase 2 | |
Recruiting |
NCT04868578 -
PPI Supplementation to Fight ECtopIc Calcification in PXE
|
N/A | |
Completed |
NCT05025722 -
Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings
|
||
Completed |
NCT01525875 -
Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)
|
Phase 2 | |
Completed |
NCT05246189 -
Employment of Patients With Pseudoxanthoma Elasticum
|